A novel pH-sensitive liposome formulation containing oleyl alcohol  by Sudimack, Jennifer J et al.
A novel pH-sensitive liposome formulation
containing oleyl alcohol
Jennifer J. Sudimack a, Wenjin Guo a, Werner Tjarks b, Robert J. Lee a,*
aDivision of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
bDivision of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
Received 16 April 2001; received in revised form 7 March 2002; accepted 7 March 2002
Abstract
pH-sensitive liposomes are designed to undergo acid-triggered destabilization. First generation pH-sensitive liposomes, based on the
cone-shaped lipid dioleoylphosphatidylethanolamine (DOPE), have been shown to lose fusogenicity in the presence of serum. Here, we
report the design and evaluation of novel serum-resistant pH-sensitive liposome formulations that are based on the composition of egg
phosphatidylcholine (PC), cholesteryl hemisuccinate (CHEMS), oleyl alcohol (OAlc), and Tween-80 (T-80). When loaded with the
fluorescent probe calcein, these liposomes exhibited excellent stability at pH 7.4 and underwent rapid destabilization upon acidification as
shown by calcein dequenching and particle size increase. Adjusting the mole percentages of T-80 and OAlc in the formulation could regulate
the stability and pH-sensitive properties of these liposomes. Liposomes with a higher T-80 content exhibited greater stability but were less
sensitive to acid-induced destabilization. Meanwhile, formulations with a higher OAlc content exhibited greater content release in response to
low pH. The pH-triggered liposomal destabilization did not produce membrane fusion according to an octadecylrhodamine B chloride (R18)
lipid-mixing assay. Compared to DOPE-based pH-sensitive liposomes, the above formulations showed much better retention of their pH-
sensitive properties in the presence of 10% serum. These liposomes were then evaluated for intracellular delivery of entrapped cytosine-h-D-
arabinofuranoside (araC) in KB human oral cancer cells, which have elevated folate receptor (FR) expression. The FR, which is amplified in
many types of human tumors, has been shown to mediate the internalization of folate-derivatized liposomes into an acidic intracellular
compartment. FR-targeted OAlc-based pH-sensitive liposomes, entrapping 200 mM araC, showed f 17-times greater FR-dependent
cytotoxicity in KB cells compared to araC delivered via FR-targeted non-pH-sensitive liposomes. These data indicated that pH-sensitive
liposomes based on OAlc, combined with FR-mediated targeting, are promising delivery vehicles for membrane impermeable therapeutic
agents. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes are phospholipid bilayer vesicles that have
been studied extensively as potential drug carriers. Major
obstacles to liposomal drug delivery have been the slow drug
release and lack of fusogenic activity of regular liposomes
following internalization into the endosomal compartment.
These factors contribute to the diminished efficiency of cyto-
solic delivery [1], especially when the encapsulated mole-
cules are large or highly hydrophilic [2–4]. In order to
overcome this obstacle, pH-sensitive liposomes have been
developed that are stable at physiological pH but are desta-
bilized upon acidification following cellular internalization,
thereby, promoting the release of their contents into the
cytosol [5–7].
Most reported formulations of pH-sensitive liposomes are
composed of dioleoylphosphatidylethanolamine (DOPE),
which has a strong propensity to form a nonbilayer structure
due to its cone-shape geometry, and a weakly acidic amphi-
phile, such as cholesteryl hemisuccinate (CHEMS), which
confers stability to the bilayer phase at neutral pH [8–12].
Under acidic conditions, CHEMS becomes partially proto-
nated, thus losing its negative charge and, therefore, its
ability to stabilize the bilayer structure, which is based on
electrostatic repulsion. This further results in the destabiliza-
tion and/or fusion of the liposomes. The DOPE-based pH-
sensitive liposomes have been shown to improve the cyto-
plasmic delivery of membrane-impermeable therapeutic
agents [7,13,14]. However, the potential application of these
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liposomes as drug carriers in vivo is hampered by their
relatively poor stability in the presence of serum [15–18].
Attempts to increase the serum stability of the DOPE-
containing liposome formulations by incorporating a poly-
ethyleneglycol (PEG)-derivatized lipid resulted in signifi-
cantly reduced pH-sensitivity [19].
The folate receptor (FR) is known to be overexpressed in a
wide variety of solid tumors as well as in myeloid leukemias
[20–22]. Folate conjugates of various therapeutic and diag-
nostic entities, including liposomes, have been shown to be
internalized by cells via FR-mediated endocytosis into an
acidic endosomal compartment [23–25]. In addition, folate-
derivatized liposomes have been shown to selectively
increase the delivery of cytotoxic drugs into tumor cells with
elevated FR expression [26]. However, highly hydrophilic
agents, such as cytosine-h-D-arabinofuranoside (araC), deliv-
ered by liposomes might be sequestered in the endosomal
compartment resulting in a slow rate of cytosolic release.
Combining FR-targeting, which promotes cellular endocy-
tosis, with pH-sensitive liposomes, which promotes endo-
somal drug release, therefore, presents an attractive approach
for improving the cytosolic delivery of araC.
In this study, we report the design and evaluation of
novel pH-sensitive liposome formulations based on the use
of oleyl alcohol (OAlc) in combination with egg phospha-
tidylcholine (PC) as the membrane destabilizing compo-
nents. The stability and pH-sensitivity of the liposomes in
buffer and in 10% serum were determined by fluorescence
dequenching assays. Furthermore, the OAlc-containing lip-
osomes, targeted to the FR, were evaluated for the intra-
cellular delivery of araC. The possible mechanism for the
pH-sensitivity of these liposomes is also discussed.
2. Materials and methods
2.1. Materials
Egg PC and DOPE were purchased from Avanti Polar
Lipids (Alabaster, AL). Octadecylrhodamine B chloride
(R18) was purchased from Molecular Probes (Eugene, OR).
Calcein, CHEMS, araC, folic acid dihydrate, 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
Sepharose CL-4B resin, Tween-80 (T-80), and Triton X-
100 were obtained from Sigma Chemical Co. (St. Louis,
MO). OAlc was purchased from Aldrich Chemical Co. (St.
Louis, MO). Polycarbonate membranes and the handheld
LiposoFastk Extruder were obtained from Avestin Inc.
(Ottawa, ON). Tissue culture media were purchased from
Life Technologies (Rockville, MD). Folate-PEG-cholesterol
(f-PEG-Chol) was synthesized as reported previously [27].
2.2. Cell culture
KB cells, a human oral cancer cell line that expresses
amplified FR, were obtained as a gift from Dr. Philip Low at
Purdue University (West Lafayette, IN). The cells were
cultured at 37 jC as a monolayer in folate-free RPMI 1640
media supplemented with antibiotics and 10% fetal bovine
serum in a humidified atmosphere containing 5% CO2.
2.3. Liposome preparations
Liposomes encapsulating calcein were prepared using a
procedure based on polycarbonate membrane extrusion, as
described previously [27]. Briefly, a chloroform solution of
the lipid mixture with the desired composition was dried into
a thin film in a round-bottom flask on a rotary evaporator, and
then further dried under vacuum. The lipid mixture was then
hydrated in 80 mM calcein. The suspension was subjected to
six cycles of freezing and thawing, briefly sonicated, and then
extruded through a 0.1 Am pore-size polycarbonate mem-
brane using a handheld LiposoFastk Extruder. Unentrapped
calcein was separated from the liposomes by gel filtration on
a Sepharose CL-4B column equilibrated in phosphate-buf-
fered saline (PBS, 136.9 mM NaCl, 2.68 mM KCl, 8.1 mM
Na2HPO4, 1.47 mMKH2PO4, pH 7.4). The mean diameter of
the extruded liposomes was determined by photon correla-
tion spectroscopy on a NICOMP Particle Sizer Model 370.
The final calcein concentrations in the liposome preparations
were calculated based on absorbance at 495 nm using a molar
extinction coefficient of 80,000 M  1 cm  1.
2.4. Membrane fusion assay
The membrane fusion assay was carried out as described
previously [28,29]. Briefly, labeled liposomes were prepared
by incorporating a lipid soluble probe, R18, at 5.7 mol% of
the total lipid, a concentration that results in fluorescence
self-quenching. Both labeled and unlabeled liposomes were
prepared at a total lipid concentration of 2 mM. These were
then mixed at a volume ratio of 1:4 (labeled/unlabeled). The
liposome mixture was diluted to 5 AM lipids in the appro-
priate buffer, followed by a 10-min incubation at 37 jC. R18
fluorescence intensity was then measured at the excitation
and emission wavelengths of 560 and 590 nm, respectively.
2.5. Fluorescence dequenching assay
Liposome content release was characterized using a cal-
cein dequenching assay, as described previously [19]. All
fluorescence measurements were performed using a Perkin-
Elmer LS-5B spectrofluorometer operated with an FTWinlab
(Morena Valley, CA) computer program. The excitation and
emission wavelengths were set at 490 and 520 nm, respec-
tively. Calcein-loaded liposomes containing 40 nmol of lipid
were added to 2 ml of PBS (adjusted to pH 7.0 and 7.4) or
sodium acetate buffer (100 mM NaCl, 10 mM acetate, pH
5.0, 5.5, 6.0, and 6.5) in a disposable cuvette. After a 10-min
incubation at 37 jC, buffer pH was adjusted to 7.4 and
calcein fluorescence was measured. The fluorescence was
then remeasured following the addition of 0.1% Triton X-
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100, which caused 100% calcein leakage from the lip-
osomes. The percent of calcein release was calculated based
on the equation:
%Calcein Release ¼ ððIpH  IoÞ=ðI100  IoÞÞ100%
where Io was the fluorescence at pH 7.4, IpH was the
fluorescence intensity following incubation at acidic buffer
pHs, and I100 was the fluorescence after the addition of
Triton X-100. In addition, the changes in the mean particle
size of the OAlc liposomes in an acidic environment were
measured at preset time intervals.
2.6. Determination of liposome stability in the presence of
serum
Liposomes entrapping 80 mM calcein and containing 40
nmol of lipid were added to 2 ml buffer at various pH values
in the presence or absence of 10% newborn calf serum.
After a 10-min incubation at 37 jC, calcein fluorescence
was measured and percentage of calcein release calculated,
as described above. In addition, liposome particle size mea-
surements were also performed at various time points.
2.7. Cytotoxicity assay
The delivery of araC by OAlc liposomes was evaluated
in KB cells. Preparation of araC-containing liposomes was
carried out by the same method used for the preparation of
calcein-containing liposomes described above, except 200
mM araC was used to hydrate the dried lipid mixture instead
of calcein. In addition, 0.5 mol% of f-PEG-Chol was incor-
porated into the lipid mixture for the preparation of FR-
targeted liposomes. The araC concentrations in the liposome
preparations were calculated based on absorbance at 280 nm
using a molar extinction coefficient of 475 M 1 cm  1,
after solubilizing the lipid membranes in a methanol/water
(2:1) mixture. The encapsulation efficiency of these lip-
osomes was found to be approximately 15%.
The cytotoxicity of various liposomal araC formulations
was determined by the MTT assay, as described previously
[30]. Briefly, KB cells were seeded in 96-well plates to
reach f 25% confluence at the time of the study. The cells
were treated in triplicate with 1:4 serial dilutions of the
various araC formulations. Following a 2 h incubation at 37
jC, the cells were then washed with PBS. Fresh media,
containing 10% fetal bovine serum, were then added and the
cells were cultured for another 48 h. MTTwas then added to
the culture medium at a concentration of 0.6 mg/ml and the
cells were incubated at 37 jC for an additional 2 h. The
medium was then removed and the cells were dissolved in
acidified isopropanol and the absorption at 495 nm was
measured using an automatic plate reader, as an indicator of
cell viability. The concentration of araC leading to 50% cell
killing (IC50) was calculated from a concentration depend-
ent cell viability curve.
3. Results
3.1. Formulation of pH-sensitive liposomes containing OAlc
All liposome compositions are described in molar ratios in
this article. The pH-sensitive liposomes were designed using
a primary lipid composition of egg PC/CHEMS (50:50)
combined with varying amounts of T-80 and OAlc. T-80
was found be necessary since, in its absence, stable liposomes
could not form at an OAlc to egg PC molar ratio above 1:2.
3.2. Effects of T-80 and OAlc content on acid-induced
liposome destabilization
We predicted that the incorporation of T-80 would confer
greater stability and reduced pH-sensitivity to egg PC-based
liposomes, whereas increasing OAlc content would have the
opposite effect. To evaluate this hypothesis, calcein-contain-
ing large unilamellar vesicles (LUV) (f 100 nm in diameter)
composed of egg PC/CHEMS/T-80/OAlc with two different
T-80 contents and escalating OAlc-to-PC ratios were pre-
pared and evaluated for pH-dependent calcein release.
First, liposomes with varying amounts of OAlc and a high
T-80 content were compared for pH-dependent content
release. As shown in Fig. 1A, liposomes composed of egg
PC/CHEMS/T-80/OAlc (50:50:5:80) released 33% of their
contents after a 10 min incubation at 37 jC at pH 5.0. In
contrast, liposomes composed of egg PC/CHEMS/T-80/OAlc
(50:50:5:20) showed only 6% calcein release under identical
conditions. These findings suggested that elevated OAlc
content resulted in increased pH-sensitivity of the liposomes.
Secondly, the above study was repeated using liposomes
with a low T-80 content. Once again, the liposomes with
higher OAlc content showed greater calcein release at acidic
pH, as shown in Fig. 1B. Furthermore, the overall amount of
calcein release was much higher compared to the above-
described liposomes with a high T-80 content. For example,
liposomes composed of egg PC/CHEMS/T-80/OAlc
(50:50:2:80) showed 83% calcein release at pH 5. These
findings suggested lowering T-80 content increased the pH-
responsiveness of the liposomes.
Thirdly, we also examined non-pH-sensitive liposomes
composed of PC/CHEMS/T-80 (50:50:2) using the same
calcein dequenching assay. As anticipated, these liposomes
showed only minimal calcein release ( < 5%) at low buffer
pH (data not shown). All liposome formulations evaluated
in this study were also found to be stable (showing < 5%
calcein leakage) over a period of 8 weeks in PBS (pH 7.4)
when stored at 4 jC.
3.3. Effect of buffer pH on liposome particle size
As shown in Fig. 2, liposomes composed of egg PC/
CHEMS/T-80/OAlc at molar ratios of 50:50:2:80 or
50:50:5:80, showed a 10- and a 15-fold increase in mean
diameter, respectively, after a 30-min incubation at pH 5.0.
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The increase in particle size was time dependent. No chan-
ges in particle sizes were observed when these liposomes
were kept in pH 7.4 buffer.
3.4. Membrane fusion assay
To determine the likely mechanism of acid-induced lip-
osomal destabilization, a membrane fusion assay based on
lipid mixing was performed using liposomes containing a
self-quenching concentration of the lipophilic probe, R18.
The composition of the R18-labeled liposomes was egg PC/
CHEMS/T-80/OAlc/R18 (50:50:2:80:5.7), whereas, the un-
labeled liposomes were composed of egg PC/CHEMS/T-80/
OAlc (50:50:2:80). Meanwhile, liposomes composed of
DOPE/CHEMS/R18 (60:40:5.7) and DOPE/CHEMS
(60:40) were used as a positive control for the above assay.
As shown in Fig. 3, the OAlc-containing liposomes did not
show a significant increase in R18 fluorescence at any pH,
suggesting a lack of membrane fusion. In contrast, R18
fluorescence from the DOPE/CHEMS liposomes gradually
increased with decreasing pH, suggesting liposomal fusion.
The degree of observed R18 fluorescence dequenching was
Fig. 2. pH-dependent particle size increase of OAlc liposomes incubated at
pH 5.0 buffer. The liposomes were composed of egg PC/CHEMS/T-80/
OAlc at molar ratios of (o) 50:50:5:80 or (.) 50:50:2:80.
Fig. 3. Acid-induced R18 fluorescence dequenching in pH-sensitive lipo-
somes. Mixtures of labeled and unlabeled liposomes (at 1:4 ratio) were
incubated for 10 min at 37 jC in buffers with a series of different pH
values. The compositions of the liposomes used were (.) DOPE/CHEMS
(60:40) and (o) egg PC/CHEMS/T-80/OAlc (50:50:2:80). Each data point
represents the mean of three parallel experiments; error bar = 1 S.D.
Fig. 1. Acid-induced calcein release from OAlc-containing liposomes with
either high (Panel A) or low (Panel B) T-80 contents. Liposomes encap-
sulating 80 mM calcein were incubated for 10 min at 37 jC in buffers with
a series of different pH values. Percent leakage of calcein was calculated
based on fluorescence measured before and after addition of Triton X-100,
as described in Materials and methods. Each data point represents the mean
of three parallel experiments; error bar = 1 S.D. The compositions of the
liposomes used were egg PC/CHEMS/T-80/OAlc at molar ratios of: in
Panel A, (.) 50:50:5:20; (n) 50:50:5:40; (E) 50:50:5:80; and in Panel B,
(.) 50:50:2:20; (n) 50:50:2:40; (E) 50:50:2:80.
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much greater at pHs below 6, which correspond to the pKa of
CHEMS.
3.5. Stability and pH-sensitivity of OAlc liposomes in the
presence of serum
For pH-sensitive liposomes to be utilized for in vivo drug
delivery, they must retain both stability and pH-sensitive
properties in the presence of serum. It has been previously
reported that serum protein binding to liposomes negatively
affect the acid-triggered destabilization of DOPE-based pH-
sensitive liposomes [15–18]. We, therefore, examined the
effect of serum on liposomes composed of egg PC/CHEMS/
T-80/OAlc (50:50:2:80), using liposomes composed of
DOPE/CHEMS (60:40) as a reference control formulation
[31]. As shown in Fig. 4, the liposomes containing OAlc
retained most of their pH-sensitive properties upon incuba-
tion with serum. Calcein release from these liposomes after
a 10-min incubation at pH 5 was 56% in the presence of
10% serum. In contrast, liposomes composed of DOPE/
CHEMS showed only 20% release under the same con-
ditions. It was noted that for both OAlc and DOPE-based
liposomes, serum exposure adversely affected the degree of
calcein release in response to low buffer pH. The OAlc-
based liposomes, however, were affected to a lesser degree,
with a decrease of calcein leakage from 83% to 56%, com-
pared to a decrease from 84% to 19% for the DOPE-based
liposomes. Serum exposure at pH 7.4 did not significantly
affect liposomal particle size over 24 h (data not shown).
3.6. Delivery of araC to KB cells by FR-targeted OAlc-
based pH-sensitive liposomes
To assess the potential utility of OAlc liposomes for
increasing cytosolic drug delivery, cytotoxicity studies were
carried out using FR-targeted liposomes entrapping araC in
cultured KB cells. f-PEG-Chol, an FR-specific targeting
ligand, was incorporated in the liposome formulation to
facilitate FR-mediated cellular uptake. No significant
change in the pH sensitivity of the targeted liposomes, as
evaluated by the calcein dequenching assay, was observed
with these liposomes (data not shown).
All araC-containing liposome formulations were found to
be stable ( < 5% leakage) over 6 weeks in PBS (pH 7.4) when
stored at 4 jC. As shown in Table 1, FR-targeted pH-
sensitive liposomal araC showed significantly elevated cyto-
toxicity, with an IC50 of 78 AM. When 1 mM free folic acid
was present during drug incubation, the cytotoxicity was
reduced by f 4-fold, with an IC50 of 312 AM, indicating
that the observed araC delivery was FR-dependent. In
contrast, FR-targeted non-pH-sensitive liposomal araC
showed a much lower cytotoxicity towards KB cells (IC50
of 1312 AM). In the absence of receptor targeting, liposomal
araC showed very low cytotoxicity (IC50>10,000 AM), even
when compared to the free drug. This was presumably due to
the lack of a cellular uptake mechanism for the liposome
entrapped drug. Empty pH-sensitive liposomes did not
contribute significantly to cellular cytotoxicity (data not
shown), as demonstrated by the resulting cytotoxicity of
the free drug/empty liposome combination. These results
indicated that both FR-targeting and a pH-sensitive liposo-
mal composition were required for the efficient intracellular
delivery of membrane-impermeable drugs, such as araC.
4. Discussion
In this study, we evaluated novel pH-sensitive liposome
formulations that were based on the incorporation of a fatty
alcohol, OAlc. This includes a detailed characterization of
the pH-sensitivity and serum stability of these liposomes.
Furthermore, we have examined the FR-specific intracellu-
Fig. 4. Effect of serum on the pH sensitivity of OAlc liposomes. Liposomes
composed of either egg PC/CHEMS/T-80/OAlc (50:50:2:80) or DOPE/
CHEMS (60:40) were compared for pH-dependent calcein release in the
presence or absence of 10% serum. Each data point represents the mean of
three parallel experiments; error bar = 1 S.D. Conditions used: (E) DOPE/
CHEMS liposomes in the presence of 10% serum; (D) DOPE/CHEMS
liposomes in buffer; (.), OAlc liposomes in the presence of 10% serum;
(o) OAlc liposomes in buffer.
Table 1
Cytotoxicity of various araC formulations in KB cells
Liposome formulationa IC50 (AM)
FR-targeted, OAlc pH-sensitive liposomal araC 78
FR-targeted, OAlc pH-sensitive liposomal
araC + 1 mM free folic acid
312
FR-targeted, non-pH-sensitive liposomal araC 1312
Non-targeted, non-pH-sensitive liposomal araC > 10,000
Free araC + empty FR-targeted, OAlc liposomes 4375
a The liposome compositions were: FR-targeted, OAlc pH-sensitive
liposomes: egg PC/CHEMS/T-80/OAlc/f-PEG-Chol (50:50:2:80:0.5); FR-
targeted, non-pH-sensitive liposomes: egg PC/CHEMS/T-80/f-PEG-Chol
(50:50:2:0.5); Nontargeted, non-pH-sensitive liposomes: egg PC/CHEMS/
T-80 (50:50:2).
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lar delivery of the anticancer drug, araC, utilizing this novel
liposomal formulation.
Previously reported formulations for pH-sensitive lip-
osomes mostly incorporate the lipid DOPE as the principal
component to promote bilayer destabilization. As shown in
Fig. 4, these liposomes tend to lose most of their pH-
sensitivity in the presence of 10% serum. Alternative com-
positions with greater resilience to serum are, therefore,
needed for in vivo drug delivery. It has been suggested that
OAlc, an unsaturated fatty alcohol, is capable of forming a
hydrogen bond through its hydroxyl to an oxygen atom on
the phosphate group on the PC molecule, resulting in the
formation of a complex with geometry similar to that of
DOPE, as illustrated in Fig. 5 [32]. This in turn could result
in a lowering of the energy barrier for the lipid transition
from a lamellar phase to a hexagonal II phase, which is
required for membrane destabilization. However, a lipid
mixing assay failed to show membrane fusion activity for
the OAlc-containing liposomes in response to low buffer pH.
Therefore, the observed pH-dependent leakage among these
liposomes entrapping calcein might primarily be due to
membrane destabilization, without inducing bilayer fusion.
Since the OAlc content in the lipid composition deter-
mines the extent of OAlc/PC complex formation, it should,
therefore, be possible to increase the pH-sensitivity of the
liposomes by increasing the OAlc content in the formula-
tion. This concept has been demonstrated by the marked
increase in calcein leakage when the OAlc content was
increased in the liposomal formulation, as shown in Fig. 1.
The potential in vivo use of pH-sensitive liposome for-
mulations is dependent on retention of their stability and
pH-sensitivity in the presence of serum. As shown in Fig. 4,
OAlc-containing liposomes demonstrated excellent stability
and pH-sensitivity in the presence of serum. In addition, the
degree of pH-sensitivity could be conveniently tuned by
altering OAlc content in the formulation. Incorporation of T-
80, which introduced a steric barrier on the surface of the
liposomes, resulted in increased liposome stability while re-
ducing its pH-dependent aggregation. Consequently, main-
taining a delicate balance between these two factors is very
important in creating an effective pH-sensitive liposomal
formulation that is optimal for drug delivery.
AraC is a cytosine analogue widely used clinically as an
anti-leukemic drug. AraC, which is highly hydrophilic, is
Fig. 5. Structures of (A) the proposed PC/OAlc complex and (B) DOPE. Note that, in both structures, the hydrophilic moieties occupy a relatively small volume
compared to the lipophilic region. This should promote the formation of nonbilayer structures and liposome destabilization.
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taken up by cells via a nucleoside transporter [33,34]. As a
cell cycle-dependent agent, araC showed relatively poor
cytotoxicity when added to cultured KB cells as a free drug
(IC50 of 4375 AM) using an exposure time of 2 h. We,
therefore, examined the effect of encapsulation of araC into
FR-targeted liposomes, both pH-sensitive and non-pH-sen-
sitive, on the in vitro cytotoxicity of this agent. As shown in
Table 1, both FR-targeting and the use of a pH-sensitive
formulation were found to be critical for maximizing lip-
osomal araC cytotoxicity.
Since folic acid has high affinity for the FR and is stable,
small, non-immunogenic, and readily available, it is ideal
for exploration as a targeting ligand. Moreover, the FR is
frequently overexpressed among human tumors, including
f 70% of acute myeloid leukemias, while being absent in
most normal tissues. FR-targeted liposomes can be readily
produced in sufficient quantities for future clinical develop-
ment. Therefore, FR-targeted OAlc liposomes, such as those
entrapping araC, might have potential utility in the treatment
of myeloid leukemias. FR-targeted delivery to solid tumors
could also be possible given the high serum stability of the
OAlc-containing liposomes, if prolonged systemic circula-
tion and efficient endothelial extravasation could be
achieved with the liposomes.
In addition to intracellular drug delivery, the pH-sensitive
liposomal formulation described here may also constitute a
drug delivery vehicle to pathological tissues, such as cancer,
inflammation and infection sites, and ischemic areas, in
which the pH is known to be lower than normal tissue [35].
Besides low molecular weight drugs such as araC, OAlc
liposomes might find utility in the delivery of bioactive
polypeptides, antisense oligodeoxyribonucleotides, as well
as plasmid DNA in the delivery of gene therapy. Further
studies on these liposomes, therefore, are warranted to
explore these potential areas of application.
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